Effect of a new sleep inducer, 1H-1,2,4-triazolyl benzophenone derivative, 450191-S on rat liver drug-metabolizing enzyme system.

Takashi Matsubara, Akira Touchi, Noriko Yamada, Shinya NishiyamaFolia 1985 · DOI

Abstract

This study investigates the impact of 450191-S, a novel triazolyl benzophenone derivative sleep inducer, on hepatic drug-metabolizing enzymes in rats. Comparisons with nitrazepam and phenobarbital revealed that 450191-S induces Cytochrome P-450-dependent enzymes at high doses (150-200 mg/kg) after 3-5 days of administration. This induction is reversible upon drug withdrawal and follows a phenobarbital-type pattern, though its potency is similar to nitrazepam and significantly weaker than phenobarbital.

Introduction

When a new medication is developed, understanding its interaction with the liver's metabolic pathways is crucial. The Cytochrome P-450 (CYP) enzyme family is responsible for breaking down most drugs. Some substances, known as "inducers," can increase the production of these enzymes, potentially leading to drug-drug interactions where co-administered medications are cleared too rapidly. This study focuses on 450191-S, a novel sleep inducer.

Chemical structure of the sleep inducer 450191-S.

Methods

The researchers administered 450191-S orally to rats and mice at various doses (50 to 600 mg/kg/day) for periods ranging from 1 to 14 days. They used several key techniques to measure the liver's response:

  • Enzyme Activity Assays: Measuring the "O-dealkylation" of 7-alkoxycoumarins (methoxy, ethoxy, and propoxy) to identify which specific P-450 enzyme sub-families are active.
  • Protein Quantification: Direct measurement of Cytochrome P-450 and cytochrome $b_5$ levels in liver microsomes.
  • Functional Testing: Using pentobarbital-induced sleeping time as a bio-assay for metabolic clearance rates.

Results

The study identified a clear "Phenobarbital-type" (PB-type) induction signature. Unlike "MC-type" inducers that target specific pathways, 450191-S increased the metabolism across all three alkoxycoumarin probes.

Alteration of hepatic 7-alkoxycoumarin O-dealkylase activity in rats following successive oral administrations of 450191-S.

Induction was dose- and time-dependent, requiring at least 150–200 mg/kg for 3–5 days to show significant effects. Importantly, this effect was fully reversible within 3–5 days of drug cessation. Functional tests confirmed these findings: rats pre-treated with 450191-S woke up significantly faster from pentobarbital-induced sleep, proving the enzymes were not just present, but actively clearing drugs faster.

In terms of relative potency, 450191-S showed inducing activity comparable to nitrazepam but significantly weaker than phenobarbital. Furthermore, unlike phenobarbital, 450191-S did not cause significant liver hypertrophy (enlargement) at the doses tested in rats.

Discussion and Limitations

While the PB-type induction pattern is evident, the specific P-450 isozymes involved require further molecular characterization. Species sensitivity varied, with mice showing induction at lower doses (50 mg/kg) than rats. These differences necessitate caution when extrapolating these findings to human clinical settings, suggesting a need for future studies in human liver models to better predict clinical drug-drug interaction risks.

Summary updated

Abstract

The effect of a new sleep inducer, 450191-S, on the hepatic drug-metabolizing enzyme system was examined using rats and compared with those of nitrazepam and phenobarbital. Cytochrome P-450-dependent 7-alkoxycoumarin O-dealkylation activity determined using liver homogenate and isolated microsomes increased after successive oral administrations of 450191-S, and induction of the enzyme system was observed by administration of 150 approximately 200 mg/kg of the drug for at least 3 approximately 5 days. Normal activity was recovered with withdrawal of the drug for 3 approximately 5 days after induction of the hepatic enzyme system. Administration of higher amounts of 450191-S (200 approximately 600 mg/kg/day) for 3 days caused remarkable increases in the O-dealkylase and UDPGA-glucuronyltransferase activities and cytochrome P-450 and b5 contents. Similar changes in the hepatic enzyme system were observed with administration of nitrazepam (200 approximately 600 mg/kg for 3 days, p.o.) or phenobarbital (10 approximately 40 mg/kg for 3 days, i.p.). We concluded that the inducing activity of 450191-S is almost the same as that of nitrazepam, but weaker than that of phenobarbital. When the hepatic enzyme system was induced by the administration of either 450191-S or phenobarbital, the pentobarbital-induced sleeping time was shortened with increasing doses of the drugs. On the other hand, sleeping time was prolonged by the administration of another type of inducer, beta-naphthoflavone. The results suggest that the inductive pattern of 450191-S is similar to that of phenobarbital.
BibTeX
@inproceedings{matsubara1985effect,
  author = {Takashi Matsubara and Akira Touchi and Noriko Yamada and Shinya Nishiyama},
  title = {{Effect of a new sleep inducer, 1H-1,2,4-triazolyl benzophenone derivative, 450191-S on rat liver drug-metabolizing enzyme system.}},
  booktitle = {Folia},
  year = {1985},
  doi = {10.1254/fpj.86.115},
}
Figure